H.C. Wainwright notes that on July 30 the American Journal of Hematology published results of a single-center, retrospective case-control study evaluating the impact of eculizumab on infection risk and infection-related mortality in pediatric patients diagnosed with thrombotic microangiopathy following allogeneic hematopoietic cell transplantation. Given that the AJH study raised caution about the potential increase in infections, complications and risk of death in using eculizumab in TA-TMA patients, the analyst believes the study could be a tailwind to narsoplimab uptake if the product is approved later this year. H.C. Wainwright has Buy rating and $9 price target on Omeros (OMER) shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMER:
- Potential Market Surge for Omeros Driven by Narsoplimab’s Edge Over Eculizumab
- Omeros Enters Securities Purchase Agreement with Polar
- Omeros to sell 5.366M shares at $4.10 in registered direct offering
- Omeros submission adds another 2026 catalyst, says H.C. Wainwright
- Omeros submits narsoplimab marketing authorization application to the EMA